Incidence of Intracranial Hemorrhage in Glioma Patients With Venous Thromboembolism Converted From LMWH to Apixaban

Inclusion Criteria: * Patients must be 18 years of age or older; * Patients must have had a pathologically confirmed supra-tentorial primary brain tumor * Patients must have history of deep venous thrombosis (DVT) and/or pulmonary embolism (PE) * Patients must have been treated with low molecule weight heparin for ≥ 5 days * Patients must be able to provide written informed consent * Patients must have non contrast CT that is negative for intra-cranial bleed at least 5 days post initiation of LMWH and prior to initiation (within 7 days) of Apixaban * Must be decision by patient and his physician to convert to Apixaban Exclusion Criteria: * Patients with a plan less than 6 months of anticoagulation for most recent DVT or PE * Patients with allergic reaction to Apixaban * Patients with active bleeding or high risk for bleeding contraindicating treatment with LMWH * Patients with planned surgery in the next 2 weeks * Patients previously treated with Apixaban * Patients requiring Acetylsalicylic Acid (ASA) greater than165 mg/day at enrollment * Patients requiring dual anti-platelet therapy (ASA plus clopidogrel or ASA plus ticlopidine) at enrollment. * Subjects with transition for dual anti-platelet therapy or monotherapy prior to enrollment will be eligible for the study * Patients who are compulsorily detained for treatment of either a psychiatric or physical (e.g. infectious disease) illness * Any condition, which in the opinion of the investigator, would put the subject at…